Peptide–drug conjugates

  1. editorImage
  1. Editor: Prof. Norbert Sewald
    Bielefeld University

Conjugates of drugs with a delivery vector targeting human diseases would be a "magic bullet" according to the early vision of Nobel laureate Paul Ehrlich. Molecules that specifically recognize and bind to structures (like membrane proteins) on the surface e.g. of a tumour cell are suitable as such a delivery vector (homing device). The recent years witnessed the regulatory approval of antibody-drug conjugates. Peptides have distinct advantages over proteins: They can have a high drug loading, easily penetrate tissue, and are easily prepared in a homogenous form with straightforward and well-defined conjugation chemistry. Hence, the development of peptide-drug conjugates is currently an important research area in bioorganic chemistry, medicinal chemistry, chemical biology, and biochemistry. Articles dealing with the development of peptide-drug conjugates for targeted delivery in tumour therapy, but also in other contexts will be considered.

Additional articles on this topic will be published here soon.

Synthesis and biological evaluation of RGD and isoDGR peptidomimetic-α-amanitin conjugates for tumor-targeting

  1. Lizeth Bodero,
  2. Paula López Rivas,
  3. Barbara Korsak,
  4. Torsten Hechler,
  5. Andreas Pahl,
  6. Christoph Müller,
  7. Daniela Arosio,
  8. Luca Pignataro,
  9. Cesare Gennari and
  10. Umberto Piarulli
  • Full Research Paper
  • Published 14 Feb 2018

  • PDF

  • Supp. Info

Beilstein J. Org. Chem. 2018, 14, 407–415, doi:10.3762/bjoc.14.29

Synthesis and in vitro biochemical evaluation of oxime bond-linked daunorubicin–GnRH-III conjugates developed for targeted drug delivery

  1. Sabine Schuster,
  2. Beáta Biri-Kovács,
  3. Bálint Szeder,
  4. Viktor Farkas,
  5. László Buday,
  6. Zsuzsanna Szabó,
  7. Gábor Halmos and
  8. Gábor Mező
  • Full Research Paper
  • Published 04 Apr 2018

  • PDF

  • Supp. Info

Beilstein J. Org. Chem. 2018, 14, 756–771, doi:10.3762/bjoc.14.64

Development of novel cyclic NGR peptide–daunomycin conjugates with dual targeting property

  1. Andrea Angelo Pierluigi Tripodi,
  2. Szilárd Tóth,
  3. Kata Nóra Enyedi,
  4. Gitta Schlosser,
  5. Gergely Szakács and
  6. Gábor Mező
  • Full Research Paper
  • Published 25 Apr 2018

  • PDF

  • Supp. Info

Beilstein J. Org. Chem. 2018, 14, 911–918, doi:10.3762/bjoc.14.78

  • Review
  • Published 26 Apr 2018

  • PDF

Beilstein J. Org. Chem. 2018, 14, 930–954, doi:10.3762/bjoc.14.80

Novel unit B cryptophycin analogues as payloads for targeted therapy

  1. Eduard Figueras,
  2. Adina Borbély,
  3. Mohamed Ismail,
  4. Marcel Frese and
  5. Norbert Sewald
  • Full Research Paper
  • Published 01 Jun 2018

  • PDF

  • Supp. Info

Beilstein J. Org. Chem. 2018, 14, 1281–1286, doi:10.3762/bjoc.14.109

  • Full Research Paper
  • Published 07 Jun 2018

  • PDF

  • Supp. Info

Beilstein J. Org. Chem. 2018, 14, 1378–1388, doi:10.3762/bjoc.14.116

  • Full Research Paper
  • Published 28 Jun 2018

  • PDF

  • Supp. Info

Beilstein J. Org. Chem. 2018, 14, 1583–1594, doi:10.3762/bjoc.14.136

Comparative cell biological study of in vitro antitumor and antimetastatic activity on melanoma cells of GnRH-III-containing conjugates modified with short-chain fatty acids

  1. Eszter Lajkó,
  2. Sarah Spring,
  3. Rózsa Hegedüs,
  4. Beáta Biri-Kovács,
  5. Sven Ingebrandt,
  6. Gábor Mező and
  7. László Kőhidai
  • Full Research Paper
  • Published 26 Sep 2018

  • PDF

  • Supp. Info

Beilstein J. Org. Chem. 2018, 14, 2495–2509, doi:10.3762/bjoc.14.226

Novel solid-phase strategy for the synthesis of ligand-targeted fluorescent-labelled chelating peptide conjugates as a theranostic tool for cancer

  1. Sagnik Sengupta,
  2. Mena Asha Krishnan,
  3. Premansh Dudhe,
  4. Ramesh B. Reddy,
  5. Bishnubasu Giri,
  6. Sudeshna Chattopadhyay and
  7. Venkatesh Chelvam
  • Full Research Paper
  • Published 18 Oct 2018

  • PDF

  • Supp. Info

Beilstein J. Org. Chem. 2018, 14, 2665–2679, doi:10.3762/bjoc.14.244

Keep Informed

RSS Feed

Subscribe to our Latest Articles RSS Feed.

Subscribe

Follow the Beilstein-Institut

LinkedIn

Twitter: @BeilsteinInst